Back to results
US 9,801,834 B2Granted
Controlled release delivery system for nasal application of neurotransmitters
AssigneeM Et P Pharma AG
InventorClaudia Mattern
Life of this patent
Estimating the term…
Abstract
This invention relates to a galenical gel formulation for nasal administration of neurotransmitters/neuromodulators such as dopamine, serotonin or pregnenolone and progesterone. The special lipophilic or partly lipophilic system of the invention leads to high bioavailability of the active ingredient in plasma and brain caused by sustained serum levels and/or direct or partly direct transport from nose to the brain.
Claims10
A dopamine gel formulation for nasal administration comprising:
- (a) dopamine in an amount of from about 0.01% to about 6% by weight of the dopamine gel formulation;
- (b) castor oil in an amount of from 75% to 95% by weight of the dopamine gel formulation;
- (c) oleoyl macrogolglyceride or a mixture of oleoyl macrogolglycerides in an amount of from 0.5% to about 20% by weight of the dopamine gel formulation;
- and
- (d) colloidal silicon dioxide in an amount of from 0.5% to 10% by weight of the dopamine gel formulation.
2 more elements
A dopamine gel formulation comprising:
- (a) dopamine in an amount of about 2% by weight of the formulation;
- (b) castor oil in an amount of about 90% by weight of the formulation;
- (c) an oleoyl macrogolglyceride or a mixture of oleoyl macrogolglycerides in an amount of about 4% by weight of the formulation;
- and (d) colloidal silicon dioxide in an amount of about 4% by weight of the formulation.
1 more element
Dependencies are inferred from the claim text.